• Admin

***Anakinra, has been approved!***

Updated: Sep 13, 2018

***Anakinra, has been approved!***

The specific conditions for which anakinra is under consideration are: - Familial Mediterranean fever (FMF)  - Hyperimmunoglobulin D Syndrome, (HIDS) also known as - Mevalonate Kinase Deficiency (MKD)  - Tumour necrosis factor receptor–associated periodic syndrome (TRAPS),  - Schnitzler syndrome

As a registered stakeholder of the Immunology and Allergy SCG, and, after collaborating with the Autoinflammatory Alliance to provide feedback on the consultation back in February, we asked for patients QoL to be considered during drug monitoring, and not just blood results. We are pleased to see that this has been taken on board in it's new Clinical Commissioning Policy.

https://www.england.nhs.uk/…/1713-anakinra-for-periodic-fev…






  • Facebook
  • Twitter
  • Instagram

Rare Autoinflammatory Conditions Community - UK (RACC - UK) ®

Contact Us: info@raccuk.com

07377091552

Registered Charity Number in England and Wales: 1184846

ICO: ZA322203 

Disclaimer: Please note that RACC - UK provides this information for the benefit of the Autoinflammatory community. RACC - UK is not a medical provider or health care facility and thus can neither diagnose any disease or disorder nor endorse or recommend any specific medical treatments. Patients must rely on the personal and individual medical advice of their qualified health care professionals before seeking any information related to their particular diagnosis, cure or treatment of a condition or disorder.

Data Protection & Cookies Policy

Terms & Conditions